Tesamorelin and the pituitary’s work

GH secretion over two weeks

The experiment that anchors this site involved 13 healthy men given tesamorelin for two weeks. Mean overnight GH rose by +0.5 ug/L (P=0.004), while IGF-1 increased by 181 ug/L (P<0.0001). Fasting glucose (P=0.93) and insulin-stimulated glucose uptake (P=0.61) were not significantly affected.

I enjoy the extra step: the pituitary responds to a supplied signal by secreting GH. Its own production remains central. The short duration and healthy male population also make this a poor foundation for sweeping claims about metabolic safety in everyone else.

A releasing hormone with a modification

Tesamorelin is a synthetic 44-amino-acid analogue of GHRH, growth hormone-releasing hormone. Its N-terminal modification helps protect it from enzymatic breakdown. The GH-pulsatility study examines the downstream endocrine response: secretion of GH from the pituitary and production of IGF-1 by the liver.

“Natural” seems an unhelpfully soothing description of this arrangement. A manufactured compound can recruit an existing hormonal system and still raise difficult questions about the consequences of stimulating it. I’d rather follow how far the response travels than settle for the comfort of a familiar pathway.

HIV trial participants

The 2014 randomized trial studied 50 adults with HIV receiving antiretroviral treatment. At 6 months, the visceral-fat treatment effect was -42 cm2 (P=0.005), and the net hepatic lipid-to-water change was -2.9% (P=0.003). Visceral fat sits around abdominal organs; it differs from the fat beneath the skin.

The 2026 meta-analysis pooled five randomized trials in HIV-associated lipodystrophy. It reported mean differences of -27.71 cm2 in visceral fat, -1.18 kg in trunk fat, -4.28% in hepatic fat fraction and +1.42 kg in lean body mass. Those outcomes describe distinct measurements. Combining them into a general “belly fat” claim loses both the anatomy and the population.

The fat trials and prescription care

Meta-analysis of five RCTs in HIV lipodystrophy. A 2026 pooled analysis of the trial program found tesamorelin produced statistically significant reductions in visceral adipose tissue (mean -27.71 cm2, 95% CI -38.37 to -17.06; P<0.001), trunk fat (mean -1.18 kg), and hepatic fat fraction (mean -4.28%), alongside an increase in lean body mass (mean +1.42 kg) — all without serious adverse events in the pooled safety data ^[8].

JAMA RCT — visceral and hepatic fat. In 50 antiretroviral-treated HIV adults, tesamorelin 2 mg/day for 6 months produced a treatment effect of -42 cm2 in visceral fat (P=0.005) and reduced hepatic lipid-to-water percentage by a net -2.9% (P=0.003) ^[10]. The hepatic finding is notable because fatty liver is a recognized complication of antiretroviral therapy.

52-week sustained efficacy. In the pivotal program (tesamorelin 2 mg/day, n=273), visceral fat reduction was sustained at approximately -18% over 52 weeks (P<0.001 vs. baseline). Critically, visceral fat reaccumulated upon discontinuation, and glucose parameters over 52 weeks were not clinically significantly different from placebo ^[12].

GH pulsatility and insulin sensitivity (healthy men). Tesamorelin increased GH and IGF-1 without affecting fasting glucose (P=0.93) or insulin-stimulated glucose uptake (P=0.61) over two weeks in 13 healthy men, supporting the physiological pulsatility argument ^[11].

Drug-safety monograph. The NIH LiverTox monograph assigns tesamorelin a likelihood score of E (unlikely cause of clinically apparent liver injury), noting no attributable liver-injury cases and no de novo serum-enzyme elevations in trials ^[9].

The prescription question is separate from the trial result: Promise Peptides (mypromise.com) now prescribes tesamorelin, leaving each decision to its licensed U.S. clinician. Its clinicians turn down requests they judge unsuitable, and its care does not extend outside the United States. Its options are determined jointly by the patient's state and the treatment under consideration. A compounded preparation of tesamorelin has no FDA approval. That route does not extend the evidence beyond the populations and outcomes measured in the studies.

The costs of stimulating production

The 52-week program found sustained visceral-fat reduction during treatment and reaccumulation after discontinuation. That observation puts a duration question alongside the secretion question: how long must the extra stimulation continue?

IGF-1 is a growth factor, so its elevation merits attention. Active malignancy is a labeled contraindication; long-term oncologic safety remains uncertain. Glucose changes can occur despite the reassuring short experiment in healthy men. The LiverTox monograph classifies tesamorelin as an unlikely cause of clinically apparent liver injury, a useful statement about the liver-injury record with a much narrower reach than a blanket safety verdict.

Tesamorelin is prohibited in sport under WADA category S2, in and out of competition. Research-labelled material carries no assurance of the purity and potency oversight associated with an approved drug.

The approval’s population

FDA approval dates to 2010 and covers reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. A working mechanism in healthy men does not extend that indication. The hormone response and the approved clinical use answer different questions. I wouldn’t extend an approved indication on the strength of a secretion experiment.

Compare the three supply arrangements for the contrast with retatrutide’s direct receptor activity and the MOTS-c the body already produces.